Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC).
Ian D. Schnadig
No relevant relationships to disclose
Manuel R. Modiano
No relevant relationships to disclose
Allen Poma
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Mary Lynne Hedley
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Robert E. Martell
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Lee Steven Schwartzberg
No relevant relationships to disclose